3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
109
Neoplasms
99
Lung Neoplasms
60
Colorectal Neoplasms
45
Prostatic Neoplasms
40
Carcinoma, Non-Small-Cell Lung
39
Pancreatic Neoplasms
33
Melanoma
31
Head and Neck Neoplasms
27
Neoplastic Cells, Circulating
25
Ovarian Neoplasms
24
Uterine Cervical Neoplasms
20
Sarcoma
19
Multiple Myeloma
19
Glioma
19
Colonic Neoplasms
19
Carcinoma, Hepatocellular
17
Leukemia, Myeloid, Acute
16
Neoplasm Metastasis
15
Squamous Cell Carcinoma of Head and Neck
14
Lymphoma
14
Glioblastoma
14
Esophageal Neoplasms
14
Endometrial Neoplasms
14
Leukemia
12
Kidney Neoplasms
11
Hematologic Neoplasms
11
Gastrointestinal Neoplasms
11
Carcinoma, Renal Cell
11
Myelodysplastic Syndromes
10
Interventions
Cyclophosphamide
9
Temozolomide
7
Radiotherapy
6
Magnetic Resonance Spectroscopy
5
Filgrastim
5
Cisplatin
5
Carboplatin
5
antineoplaston AS 2-1
4
antineoplaston A10
4
Etoposide
4
sargramostim
3
Vincristine
3
Thiotepa
3
Melphalan
3
Automobiles
3
fludarabine
2
aldesleukin
2
Thalidomide
2
Surveys and Questionnaires
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Gadolinium DTPA
2
Eflornithine
2
Donepezil
2
Carmustine
2
Biopsy
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
trifluridine tipiracil drug combination
1
trametinib
1
thymoglobulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroectodermal Tumors, Primitive
×
Blood Specimen Collection
×
Clear all
NCT06861244
2026-04-23
PNOC031
University of California, San Francisco
Phase 2
Recruiting
70 enrolled